Featured Download

Dos And Dont’s For Quality Preservation In Compound Management

Dos And Dont’s For Quality Preservation In Compound Management

Successful drug discovery relies heavily on having efficient compound management systems in place, providing access to a growing library of high quality compounds and samples and having sufficient automation technologies to handle them.

Therefore, preserving the quality of samples is at the heart of compound management. Pharma IQ consulted with a selection of experts for their insight on the best ways to enhance sample integrity.
Gaining Access to Diverse Samples- The Web of Collaboration

Gaining Access to Diverse Samples- The Web of Collaboration

In this infographic Pharma IQ examines the web of collaboration between biobanks both public and commercial, pharma firms, biotech firms and academia in regards to biological sample management. This piece also breaks down the finer details of these collaborations including mapping the traditional motivations of each parties,
providing tips for improvement and assessing the usual stumbling blocks.
Biobanking – Creating a Collaborative Approach between Academia & Industry

Biobanking – Creating a Collaborative Approach between Academia & Industry

In this interview Arndt Schmitz, Head of Research Biobank, Bayer Pharma AG, speaks about creating a collaborative approach between academia and industry, the associated hurdles when technology is transferred from academia to industry and measuring successful collaboration in biobanking.
Biobanking - Evaluating the Benefits of Public-Private Partnerships

Biobanking - Evaluating the Benefits of Public-Private Partnerships

Cutting edge research as well as further innovations in the life science industry will strongly depend on transnational access to high quality human biological data derived from samples, and to the associated medical information, all of which must be accessible to both academia and industry in an efficient and secure manner. In this interview Heli Salimen-Mankonen, Research Director, Auria Biobank, speaks about forming and sustaining public-private partnerships and the evaluating the benefits of this collaboration.
High-Throughput Screening: Best Practice, Trends and Challenges

High-Throughput Screening: Best Practice, Trends and Challenges

Read this article for the latest trends and challenges in high-throughput screening (HTS), one of the most important and valuable areas for the pharmaceutical industry, particularly in the field of drug discovery. Read more here.
Spex agenda download

Spex agenda download

Download the 2017 agenda to view the full speaker line up and topic sessions.

IT Issues In Sample Management: Troubleshooting

IT failures have the power to incur large financial costs and productivity costs. Work could be jeopardised when compounds or biological samples can’t be retrieved when needed for experiments or screens that have taken up a lot of preparation time. In our 2016 Activity tracker report, automation was seen as a priority and an investment must. Compound management respondents stated that system maintenance & automation stood as predominant challenges for them to tackle. This troubleshooting ebook will explore aspects to consider in your decision making.
Compound & Biosample Management 2017 Market Trend Report

Compound & Biosample Management 2017 Market Trend Report

Compound management and biological sample management both have significant influence in the drug discovery process. Compounds of a high integrity contribute to reliable results when locating drug candidates. Additionally, the collection, storage and distribution of human biological materials supports the advancement of the R&D industry, aids understanding of the mechanisms of diseases and fuels the trend to provide personalised medicines.

Last year in Pharma IQ’s Compound Management and Biobanking Activity tracker, around 20 compound management industry members and 28 biobanking industry members examined and pinpointed the most recent trends in both markets over the past year and the predicted trends on the horizon.

This year, we revisit the compound and biobanking markets to pinpoint any shifts or new trends in the market.